Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING

Biology of Juvenile Myoclonic Epilepsy

NCT03400371 · View on ClinicalTrials.gov ↗

Study Summary

The investigators are collecting genetic information through blood samples as well as clinical and EEG data from over 1000 people with Juvenile Myoclonic Epilepsy (JME) across the UK, Europe and North America. This study will draw on both existing and new samples from JME patients. These will be compared to anonymised data from samples for 2000 controls. The goal of this study is to find the genetic cause of JME. Finding the cause will help create better treatments for JME, as well as improve patient outcomes by allowing us to detect it earlier.

Interventions

  • OTHER Blood draw
  • OTHER Existing samples

Study Locations (15)

Other

  • Charles University — Prague
  • Danish National Epilepsy Centre — Dianalund
  • Tallinn Children's Hospital — Tallinn
  • University Robert Debré — Paris
  • Commissione Genetica Lega Italiana contro l'Epilepssia — Roma
  • Vestre Viken Health Trust, Oslo — Drammen
  • Walton Centre for Neurology and Neurosurgery — Liverpool
  • Royal London Hospital — London
  • St Thomas' Hospital — London
  • King's College Hospital NHS Trust — London
  • Swansea University — Swansea

New York

  • Mount Sinai-Beth Israel Medical Center — New York
  • St Luke's Roosevelt Hospital — New York

Ohio

  • Nationwide Children's Hospital — Columbus

Ontario

  • Hospital for Sick Kids — Toronto

Trial Details

FieldValue
Enrollment Target 1,000 participants
Start Date 2017-07-13
Est. Completion 2026-12-31

Sponsor

King's College London

2 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03400371

The ClinicalTrials.gov registry entry for NCT03400371 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is King's College London, which has 2 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Juvenile Myoclonic Epilepsy appearing as the primary indexed condition, and to 2 interventions — of which Blood draw is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT03400371 reports 15 study locations spanning 4 distinct geographic areas — top geographies include Other, New York, Ohio. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT03400371 about?

NCT03400371 is a clinical study titled "Biology of Juvenile Myoclonic Epilepsy". The investigators are collecting genetic information through blood samples as well as clinical and EEG data from over 1000 people with Juvenile Myoclonic Epilepsy (JME) across the UK, Europe and North America. This study will draw on both existing and new samples from JME patients. These will be com...

What is the current status of trial NCT03400371?

This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2017-07-13. Estimated completion is 2026-12-31.

What conditions does trial NCT03400371 study?

This clinical trial studies the following conditions: Juvenile Myoclonic Epilepsy. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT03400371?

The interventions under investigation include: Blood draw (OTHER), Existing samples (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT03400371?

This trial is sponsored by King's College London, which has 2 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT03400371 being conducted?

This trial has 15 study locations across New York, Ohio, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial